ArticleArchives of osteoporosis2025
The impact of biological age and age acceleration on 1-year mortality rates in elderly hip fracture patients: a prospective cohort study.
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examines how biological age, calculated from routine lab tests, predicts 1-year mortality in elderly hip fracture patients better than chronological age. Our findings highlight that increased biological aging is linked to higher mortality, emphasizing its potential for improving preoperative risk assessment.
introductionGeriatric hip fractures cause high morbidity and up to 30% 1-year mortality. Incorporating biological age and age acceleration into traditional assessments may improve predictions of outcomes and guide clinical interventions and perioperative counseling.
methodsIn this prospective study, patients aged ≥ 50 with low-energy hip fractures had demographic data, chronological age, comorbidities, and nine laboratory parameters collected preoperatively. Biological age was computed per Levine et al. (2018), and age acceleration was defined as the difference between biological and chronological age. Patients were categorized by age acceleration (< 20 vs. ≥ 20 years) and into four subgroups (-15 to 5, 5-20, 20-30, and ≥ 30 years) for survival analysis.
resultsNinety-one patients were included. Mean chronological age was 76.6 (SD 9.2) years, biological age 90.5 (SD 15.0) years, and age acceleration 13.9 (SD 13.1) years; the mean Charlson Comorbidity Index was 4.1 (SD 3.1). One-year mortality was 25.3%. Those who died had higher CCI (6.0 vs. 3.5; p = 0.001), biological age (102.6 vs. 86.4; p < 0.001), and age acceleration (23.8 vs. 10.7; p < 0.001). Mortality increased from 7.7% in the lowest (-15 to 5 years) to 63.6% in the highest (≥ 30 years) age acceleration bracket. Cox regression-adjusted for ambulation, race, sex, CCI, and smoking-confirmed age acceleration ≥ 20 years as an independent predictor (HR 3.27; 95% CI 1.28-8.38; p = 0.014).
conclusionBiological age and age acceleration outperform chronological age in predicting 1-year mortality, supporting their role in risk stratification for geriatric hip fracture patients.
Indexed as
Identifiers
40569331What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.